Rapid pulmonary phospholipid accumulation induced by intravenous amiodarone.
Amiodarone causes accumulation of phospholipids in lung alveolar cells, and this phospholipidosis invariably is present when amiodarone pulmonary toxicity is recognized. This effect has usually been demonstrated in patients following several months of therapy. The authors report the occurrence of pulmonary phospholipidosis, diagnosed by bronchoalveolar lavage, six days after commencing intravenous amiodarone therapy.
Lapinsky
S E
SE
Department of Medicine, Mount Sinai Hospital, Toronto, Ontario.
Mullen
J B
JB
Balter
M S
MS
D000368:Aged; D000638:Amiodarone / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D007262:Infusions, Intravenous; D008168:Lung / Q000187:drug effects / Q000378:metabolism*; D008171:Lung Diseases / Q000139:chemically induced*; D008297:Male; D010743:Phospholipids / Q000378:metabolism*; D013997:Time Factors; D014693:Ventricular Fibrillation / Q000188:drug therapy
D010743:Phospholipids; D000638:Amiodarone